0001209191-18-034058.txt : 20180529 0001209191-18-034058.hdr.sgml : 20180529 20180529214715 ACCESSION NUMBER: 0001209191-18-034058 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180525 FILED AS OF DATE: 20180529 DATE AS OF CHANGE: 20180529 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harland John M CENTRAL INDEX KEY: 0001546788 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35285 FILM NUMBER: 18866386 MAIL ADDRESS: STREET 1: C/O WAFERGEN BIO-SYSTEMS, INC. STREET 2: 7400 PASEO PADRE PARKWAY CITY: FREMONT STATE: CA ZIP: 94555 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxart, Inc. CENTRAL INDEX KEY: 0000072444 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 591212264 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 290 UTAH AVE., SUITE 200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 550-3500 MAIL ADDRESS: STREET 1: 290 UTAH AVE., SUITE 200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Aviragen Therapeutics, Inc. DATE OF NAME CHANGE: 20160413 FORMER COMPANY: FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20121113 FORMER COMPANY: FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS DATE OF NAME CHANGE: 20100719 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-05-25 0 0000072444 Vaxart, Inc. VXRT 0001546788 Harland John M 290 UTAH AVE., SUITE 200 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Financial Officer Stock Option (right to buy) 5.17 2018-05-25 4 A 0 18000 0.00 A 2028-05-24 Common Stock 18000 18000 D The shares subject to this Option shall vest as follows: 1/4th of the total number of shares subject to the Option shall vest on the day preceding the 12-month anniversary of the vesting commencement date of February 13, 2018 and 1/48th of the total number of shares subject to the Option shall vest on the day preceding each monthly anniversary of the vesting commencement date thereafter. /s/ Wouter W. Latour, M.D., Attorney-in-Fact 2018-05-29